Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors
June 22 2021 - 8:00AM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device
company focused on developing products to treat and transform the
lives of patients suffering from venous diseases, today announced
the appointment of Ms. Rebecca Chambers to its board of directors.
Ms. Chambers also will serve as a member of the Audit Committee.
Ms. Chambers, currently Chief Financial Officer of Outset Medical,
Inc., brings more than a decade of healthcare leadership
experience. Over the course of her career, Ms. Chambers has led
numerous financial functions as well as served in leadership roles
in investor relations for publicly traded companies in the
healthcare space.
“We are pleased to welcome Rebecca as a new independent director
to our board. Her extensive healthcare leadership experience in
high growth companies will be a valuable asset to Inari as we
continue revolutionizing the treatment of venous thromboembolism,”
said Bill Hoffman, Inari’s Chief Executive Officer.
Since June 2019, Ms. Chambers has served as the Chief Financial
Officer of Outset Medical, Inc., a NASDAQ listed medical technology
company pioneering a novel technology to reduce the cost and
complexity of dialysis. Prior to that, she was at Illumina, a
NASDAQ listed genetic tools company, where she served in a number
of roles: as the Vice President, Financial Planning and Analysis
from July 2017 to May 2019, as Vice President, Investor Relations
and Treasury from April 2015 to June 2017, and as Senior Director,
Investor Relations from October 2012 to April 2015. Previously, Ms.
Chambers served as Head of Investor Relations and Corporate
Communications at Myriad Genetics, a NASDAQ listed molecular
diagnostic company, from January 2011 to October 2012, and in
various roles in investor relations at Life Technologies, a
biotechnology company, from May 2009 to December 2010. She also
previously held positions with Bank of America, a financial
services company, and Millennium Pharmaceuticals, a
biopharmaceutical company that was acquired by Takeda
Pharmaceuticals Co. Ms. Chambers holds a B.S. from John Carroll
University and an M.B.A. from The S.C. Johnson Graduate School of
Management, Cornell University.
About Inari Medical, Inc.Inari Medical, Inc. is
a medical device company focused on developing products to treat
and transform the lives of patients suffering from venous diseases.
Inari has developed two minimally-invasive, novel catheter-based
mechanical thrombectomy devices that are designed to remove large
clots from large vessels and eliminate the need for thrombolytic
drugs. The company purpose-built its products for the specific
characteristics of the venous system and the treatment of the two
distinct manifestations of venous thromboembolism, or VTE: deep
vein thrombosis and pulmonary embolism. The ClotTriever system is
510(k)-cleared by the FDA and CE Mark approved for the treatment of
deep vein thrombosis. The FlowTriever system is 510(k)-cleared by
the FDA and CE Mark approved for the treatment of pulmonary
embolism and clot in transit in the right atrium.
Investor Contact:Westwicke PartnersCaroline
CornerPhone +1-415-202-5678 caroline.corner@westwicke.com
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Apr 2023 to Apr 2024